Cases & Deals

  • Home
  • Practices
  • Bristol Myers Squibb and Bain Capital create new company dedicated to developing innovative immunology therapies

Share

Bristol Myers Squibb and Bain Capital create new company dedicated to developing innovative immunology therapies

July 2025

Client(s) Bristol Myers Squibb

Jones Day acted as tax counsel to Bristol Myers Squibb in the creation of a new independent biopharmaceutical company with Bain Capital focused on developing new therapies for autoimmune diseases that address significant unmet needs of patients. The newly formed company launches with five immunology assets in-licensed from BMS and a $300 million financing commitment that was led by Bain Capital.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.